Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Interest Expenses (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Interest Expenses for 16 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 102.15% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, up 55.46% year-over-year, with the annual reading at $4.7 million for FY2025, 55.25% up from the prior year.
  • Interest Expenses hit $1.8 million in Q4 2025 for Ligand Pharmaceuticals, up from $910000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $5.8 million in Q1 2021 to a low of $1000.0 in Q3 2023.
  • Historically, Interest Expenses has averaged $1.5 million across 5 years, with a median of $828000.0 in 2022.
  • Biggest five-year swings in Interest Expenses: plummeted 99.7% in 2023 and later soared 74000.0% in 2024.
  • Year by year, Interest Expenses stood at $4.5 million in 2021, then plummeted by 94.62% to $240000.0 in 2022, then tumbled by 45.42% to $131000.0 in 2023, then surged by 574.05% to $883000.0 in 2024, then soared by 102.15% to $1.8 million in 2025.
  • Business Quant data shows Interest Expenses for LGNDZ at $1.8 million in Q4 2025, $910000.0 in Q3 2025, and $1.2 million in Q2 2025.